- Home
- VYGR
as 07-26-2024 4:00pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Upcoming Earnings Alert:
Get ready for potential market movements as Voyager Therapeutics Inc. VYGR prepares to release earnings report on 01 Aug 2024.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 447.7M | IPO Year: | 2015 |
| Target Price: | $18.00 | AVG Volume (30 days): | 502.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.06 - $11.72 | Next Earning Date: | 08-01-2024 |
| Revenue: | $119,044,000 | Revenue Growth: | -37.58% |
| Revenue Growth (this year): | -80.21% | Revenue Growth (next year): | 6.88% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandrock Alfred | VYGR | President and CEO | Apr 2 '24 | Sell | $9.86 | 12,115 | $119,453.90 | 322,839 | SEC Form 4 |
| Swartz Robin | VYGR | Chief Operating Officer | Apr 2 '24 | Sell | $9.88 | 1,357 | $13,407.16 | 117,004 | SEC Form 4 |
| Sandrock Alfred | VYGR | President and CEO | Feb 21 '24 | Sell | $7.46 | 13,033 | $97,226.18 | 334,954 | SEC Form 4 |
| PFREUNDSCHUH PETER P. | VYGR | Chief Financial Officer | Feb 21 '24 | Sell | $7.46 | 3,764 | $28,079.44 | 175,669 | SEC Form 4 |
| Swartz Robin | VYGR | Chief Operating Officer | Feb 21 '24 | Sell | $7.45 | 3,966 | $29,546.70 | 118,361 | SEC Form 4 |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 20 '24 | Sell | $7.68 | 602 | $4,623.36 | 90,992 | SEC Form 4 |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 20 '24 | Sell | $7.47 | 3,365 | $25,136.55 | 87,627 | SEC Form 4 |
| Swartz Robin | VYGR | Chief Operating Officer | Jan 17 '24 | Sell | $7.15 | 2,543 | $18,182.45 | 72,327 | SEC Form 4 |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Jan 17 '24 | Sell | $7.18 | 1,266 | $9,089.88 | 53,094 | SEC Form 4 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
17 days ago
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
22 days ago
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is definitely on the radar of institutional investors who own 49% of the company
GlobeNewswire
a month ago
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
MT Newswires
a month ago
Voyager Therapeutics Names Nathan Jorgensen as Finance Chief
GlobeNewswire
a month ago
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.